The company has received a warning letter from the United States Food and Drug Administration (USFDA) relating to our unit XI, active pharmaceutical ingredient (API) manufacturing facility situated at Srikakulam District, Andhra Pradesh. This action follows the earlier inspection of the site by the USFDA in February 2019, Aurobindo Pharma said in BSE filing.Aurobindo Pharma gets warning letter from USFDA for Andhra unit
The company has received a warning letter from the United States Food and Drug Administration (USFDA) relating to our unit XI, active pharmaceutical ingredient (API) manufacturing facility situated at Srikakulam District, Andhra Pradesh. This action follows the earlier inspection of the site by the USFDA in February 2019, Aurobindo Pharma said in BSE filing.
Subscribe to:
Post Comments (Atom)
-
Huawei faces international scrutiny over its ties with the Chinese government and suspicion that Beijing could use Huawei#39;s technology f...
-
The company did not export units last month while it had dispatched 804 Etios units in in June 2019.
-
"Paytm is now empowering feature phone users to recharge for their Vodafone Idea numbers with just a valid UPI ID. Along with the tele...
No comments:
Post a Comment